MAX-10181 Given Orally to Patients With Advanced Solid Tumor
This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.
Solid Tumor
DRUG: MAX-10181
Adverse events (AEs), Incidence of treatment-related AEs, 8 weeks|Maximum tolerated dose (MTDï¼‰, MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing., 4 weeks|Phase II dose (RP2D), The number and proportion of patients experiencing at least 1 dose-limiting toxicity (DLT) will be used as the primary measure to evaluate the RP2D of MAX-10181., 4 weeks
Tmax, Time to maximum plasma concentration, Approximately 4 weeks|Cmax, Time to maximum plasma concentration, Approximately 4 weeks|AUC, Area under the time-concentration curve, Approximately 4 weeks|t1/2, Observed terminal half-life, Approximately 4 weeks|Objective response rate (ORR), The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1., 12 months (anticipated)
This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.